Precision-Driven Innovation and Evolving Paradigms: Final Overall Survival Analysis of the JUPITER-06 Trial

Key Points

• To evaluate the overall survival and efficacy of immunotherapy combined with chemotherapy in advanced esophageal squamous cell carcinoma.
• Conducted as a Phase III trial (JUPITER-06)
• Compared treplizumab plus paclitaxel and cisplatin to traditional chemotherapy
• Analyzed resistance mechanisms like SWI/SNF complex loss and WNT pathway activation.
• Median overall survival was 17.7 months in the treatment group, extending 4.8 months compared to chemotherapy alone (p<0.05).
• Three-year overall survival rate improved by nearly 10% with the combination treatment.
• Established a framework for personalized immunotherapy based on ccTMB and genomic immune typing.